share_log

Pfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double -- 6th Update

Pfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double -- 6th Update

辉瑞上调新冠肺炎疫苗预估销售额增长逾一倍--第6次更新
Dow Jones Newswires ·  2021/11/02 21:06

By Jared S. Hopkins and Matt Grossman
贾里德·S·霍普金斯和马特·格罗斯曼著

Pfizer Inc. increased its forecast for sales of its Covid-19 vaccine this year to about $36 billion, a roughly 7% boost that comes as the U.S. prepares to distribute the shot to 28 million children ages 5 to 11 years old.

辉瑞公司(Pfizer Inc.)将今年新冠肺炎疫苗的销售额预期上调至约360亿美元,增幅约为7%。与此同时,美国正准备向2,800万名5至11岁的儿童发放疫苗。

The New York-based drugmaker said its sales projection for the vaccine it developed with partner BioNTech SE takes into account expected deliveries of about 2.3 billion vaccine doses this year. The companies have grown their capabilities for manufacturing doses, and are working with other firms overseas to produce doses.

这家总部位于纽约的制药商表示,其与合作伙伴BioNTech SE开发的疫苗的销售预测考虑到了今年预计交付的约23亿剂疫苗。这些公司已经提高了制造剂量的能力,并正在与海外其他公司合作生产剂量。

The vaccine's revenue of $13 billion was the biggest contributor to Pfizer's third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Pfizer Chief Executive Albert Bourla said on an earnings call.

该疫苗130亿美元的收入是辉瑞第三季度销售额约240亿美元的最大贡献者,同比增长了一倍多。辉瑞首席执行长鲍拉(Albert Bourla)在财报电话会议上说,今年超过75%的疫苗销售来自国际销售,因为疫苗已经到达152个国家。

The vaccine remains in global demand in countries that are receiving initial supplies and others that have begun booster campaigns, as well as those that have yet to receive any supplies at all. The U.S. has authorized additional shots of the vaccine for many high-risk adults and last week cleared use of the vaccine for children as young as 5 years old.

在接受初始供应的国家和其他已经开始加强宣传活动的国家,以及那些还没有收到任何供应的国家,疫苗仍然是全球需求。美国已经批准为许多高危成年人额外注射疫苗,并于上周批准了对年仅5岁的儿童使用疫苗。

In the U.S., the vaccine is expected to be available to the young children as soon as Wednesday in some locations, because the Centers for Disease Control and Prevention on Tuesday night endorsed use of the shot in the children. The agency's endorsement was the last step before the vaccines could be administered, after the Food and Drug Administration authorized use outside clinical trials last week. Booster shots of the vaccine were cleared in September for many high-risk adults.

在美国,由于美国疾病控制和预防中心(Centers For Disease Control And Prevention)周二晚间批准在儿童身上注射疫苗,预计最早将于周三在一些地方向幼儿提供疫苗。在美国食品和药物管理局(Food and Drug Administration,简称FDA)上周批准在临床试验之外使用疫苗后,FDA的认可是疫苗可以接种之前的最后一步。9月份,许多高危成年人获得了疫苗的强化注射。

Pfizer is planning to produce about four billion doses next year, but has secured orders for 1.7 billion doses. The number of orders shows it is meeting demand, and low-income countries should move to strike supply deals before wealthy countries, to avoid falling behind as they did in the world's initial vaccine rollout, Mr. Bourla said in an interview.

辉瑞计划明年生产约40亿剂,但已获得17亿剂的订单。鲍拉在接受采访时说,订单数量表明它正在满足需求,低收入国家应该在富裕国家之前达成供应协议,以避免像它们在全球最初推出疫苗时那样落后。

"We are already going way above what we forecast is needed based on the orders we have," Mr. Bourla said. "If there are orders we will make more next year."

“根据我们的订单,我们已经远远超出了我们预测的需求量,”布拉说。“如果有订单,我们明年就会有更多订单。”

While data from Pfizer and other researchers have shown an additional dose might increase protection, a trial studying a fourth dose of the vaccine could start next spring, about a year after trial subjects in its studies received third doses, said Pfizer Chief Scientific Officer Mikael Dolsten in an interview.

辉瑞首席科学官米凯尔·多尔斯滕(Mikael Dolsten)在接受采访时表示,虽然辉瑞和其他研究人员的数据显示,额外的剂量可能会增强保护作用,但研究第四剂疫苗的试验可能会在明年春天开始,也就是研究中的试验对象接种第三剂疫苗大约一年后。

That could lead to study results in time for people to get a fourth dose when they get flu shots.

这可能会导致研究结果及时出现,以便人们在接种流感疫苗时获得第四剂疫苗。

"It's really to prepare for what we think is the very likely need for annual revaccinations," he said.

他说:“这真的是在为我们认为很可能需要进行的年度复审做准备。”

The company recently said that a third dose was found in a large study to be safe and highly protective against symptomatic Covid-19.

该公司最近表示,在一项大型研究中发现,第三剂新冠肺炎是安全的,对有症状的新冠肺炎具有高度保护作用。

The vaccine's revenue of $13 billion was the biggest contributor to Pfizer's third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Mr. Bourla said.

该疫苗130亿美元的收入是辉瑞第三季度销售额约240亿美元的最大贡献者,同比增长了一倍多。布拉说,今年超过75%的疫苗销售来自国际销售,因为疫苗已经到达152个国家。

Pfizer said it expects initial results on its experimental Covid-19 antiviral, which is in late-stage testing, by the end of the first quarter of 2022. Researchers are studying the drug in both vaccinated and unvaccinated people, and low-risk individuals, which could differentiate it from a promising antiviral from Merck & Co. and Ridgeback Biotherapeutics LP under review by the Food and Drug Administration.

辉瑞公司表示,预计其实验性新冠肺炎抗病毒药物的初步结果将于2022年第一季度末公布,该药物正处于后期测试阶段。研究人员正在疫苗接种和未接种疫苗的人群以及低风险人群中研究这种药物,这可能会将其与默克公司(Merck&Co.)和美国食品和药物管理局(Food And Drug Administration)正在审查的Ridgeback BioTreateutics LP的一种有前途的抗病毒药物区分开来。

The company has begun providing scientific data to the FDA, although it hasn't formally requested authorization. Pfizer will be able to deliver doses this year, if authorized, Mr. Bourla said.

该公司已经开始向FDA提供科学数据,尽管它还没有正式请求授权。鲍拉说,如果获得授权,辉瑞今年将能够提供剂量。

Pfizer expects as many as 150 million adults globally could need the antiviral because of infections and close contacts, said Pfizer Biopharmaceuticals President Angela Hwang. She said that there is potential for long-term sales and for government contracts for stockpiling.

辉瑞生物制药总裁安吉拉·黄(Angela Hwang)表示,辉瑞预计全球可能有多达1.5亿成年人由于感染和密切接触而需要抗病毒药物。她说,有可能进行长期销售,也有可能与政府签订储备合同。

Pfizer forecast $29 billion in sales next year off the 1.7 billion doses, reflecting the durability of long-term sales and efforts by countries to curb the spread of the virus in winter months. Mr. Bourla said many countries will be purchasing pediatric doses. Next year's revenue is likely to be even higher because the forecast reflects supply agreements signed through mid-October.

辉瑞预计,在17亿剂的基础上,明年的销售额将达到290亿美元,这反映了长期销售的持久性,以及各国在冬季几个月遏制病毒传播的努力。布拉说,许多国家将购买儿科用药。明年的营收可能更高,因为预估反映的是截至10月中旬签署的供应协议。

Should the sales materialize, they would make the Pfizer-BioNTech vaccine the bestselling pharmaceutical product of all time. The world's top-selling prescription drug in recent years has been AbbVie Inc.'s anti-inflammatory drug Humira, which sold nearly $20 billion in 2018.

如果销售成为现实,他们将使辉瑞-生物科技疫苗成为有史以来最畅销的医药产品。近年来全球最畅销的处方药是艾伯维公司的抗炎药Humira,该药在2018年的销售额接近200亿美元。

Pfizer splits vaccine sales with BioNTech.

辉瑞与BioNTech平分疫苗销售。

The outlook for Pfizer's vaccine reflects the preference of the vaccine over ones from its rivals. Nearly 200 million Americans have been fully vaccinated, with more than half receiving Pfizer-BioNTech shots. Most of the rest received the vaccine from Moderna Inc. that uses a similar mRNA-based technology.

辉瑞(Pfizer)疫苗的前景反映出,相对于竞争对手的疫苗,辉瑞对该疫苗的偏好程度更高。近2亿美国人已经完全接种了疫苗,超过一半的人接受了辉瑞-生物科技(Pfizer-BioNTech)的注射。其余的大多数人接种了来自现代公司的疫苗,该公司使用了类似的基于mRNA的技术。

Pfizer has also distributed two billion doses so far and is on track to produce three billion doses.

到目前为止,辉瑞公司也已经分发了20亿剂,并正在按计划生产30亿剂。

Mr. Bourla in the interview urged poor countries to secure supply -- at discounted or not-for-profit prices -- for next year, and that he wants to avoid repeating another year in which they lagged behind wealthier countries. He said he hopes the World Health Organization and Covax can help.

布拉在接受采访时敦促穷国以折扣价或非盈利性价格确保明年的供应,他希望避免重蹈它们落后于富裕国家的覆辙。他说,他希望世界卫生组织和Covax能提供帮助。

The Covax program, run by a number of organizations including Unicef and the WHO, was created with the intention to offer rich and poor nations equitable access to vaccines.

Covax计划由包括联合国儿童基金会和世界卫生组织在内的多个组织运营,旨在为富国和穷国提供平等的疫苗接种机会。

Mr. Bourla said he has sent letters to countries asking them to place orders, and said they should be more proactive than in the past.

布拉说,他已经致函各国要求他们下订单,并说他们应该比过去更积极主动。

"Some governments are better than others," he said. "That's the problem."

他说:“一些政府比其他政府做得更好。”“这就是问题所在。”

Pfizer and other vaccine makers are facing criticism from countries, public-health officials and drug-access advocates for not supplying enough doses to low- and middle-income countries. Some countries lacked funds to secure deals with companies or the knowledge to make their own shots, forcing them to rely on the Covax program. Countries with supply deals have also been hampered by inadequate infrastructure needed to refrigerate vaccines.

辉瑞和其他疫苗制造商正面临来自各国、公共卫生官员和药物获取倡导者的批评,因为它们没有向低收入和中等收入国家提供足够的剂量。一些国家缺乏与公司达成交易的资金,也缺乏自己动手的知识,迫使它们依赖于Covax计划。有供应协议的国家也受到冷藏疫苗所需基础设施不足的阻碍。

Only 3.7% of people in low-income countries have received at least one dose of a Covid-19 vaccine, according to Our World in Data. Some critics have proposed governments waive intellectual-property rights to spur production, an idea rejected by vaccine makers.

根据世界卫生组织的数据,低收入国家中只有3.7%的人接种了至少一剂新冠肺炎疫苗。一些批评人士建议政府放弃知识产权以刺激生产,这一想法遭到疫苗制造商的拒绝。

The Pfizer-BioNTech vaccine is expected to be available soon in the U.S. to children as young as 5 years old, after U.S. health authorities last week authorized its emergency use as the first Covid-19 shot for the youngsters. The shot is fully approved for people 16 years and up, and is cleared for emergency use in children 12 and older.

辉瑞-生物科技疫苗预计很快就会在美国向5岁的儿童提供,上周美国卫生当局授权紧急使用该疫苗,作为这些年轻人的第一针新冠肺炎疫苗。该疫苗完全批准16岁及以上人群使用,并允许12岁及以上儿童紧急使用。

U.S. regulators have cleared boosters for people vaccinated with the Pfizer-BioNTech vaccine at least six months after their second dose, as long as they are seniors or at high risk because of underlying medical conditions or their workplace. The regulators have since broadened availability of boosters to people who received Moderna or Johnson & Johnson.

美国监管机构已经批准为接种辉瑞-生物技术疫苗的人提供增强剂,只要他们是老年人或由于潜在的医疗条件或工作场所的高风险,在接种第二剂疫苗至少六个月后就可以接种。自那以后,监管机构扩大了对接受莫迪纳或强生疫苗的人的免疫接种范围。

The Pfizer-BioNTech vaccine has advanced through clinical trials and regulatory hurdles faster than rival shots cleared for use in adults.

辉瑞-生物科技(Pfizer-BioNTech)疫苗通过临床试验和监管障碍的速度比获准在成年人身上使用的竞争对手疫苗的速度更快。

Initial results from a clinical study of the Pfizer-BioNTech vaccine in children 2 to 4 years are expected by the end of the year, while data for children 6 months to under 2 should be in by the end of next quarter, Dr. Dolsten said.

多尔斯滕博士说,辉瑞生物科技(Pfizer-BioNTech)疫苗在2至4岁儿童中的临床研究的初步结果预计将于今年年底公布,而6个月至2岁以下儿童的数据应会在下个季度末公布。

Moderna said recently it won't seek approval for its vaccine's use in young children until the FDA clears the shots for teenagers. Johnson & Johnson, the third vaccine cleared for use in the U.S., is studying the shot in teens but hasn't started studying it yet in younger children.

莫德纳最近表示,在FDA批准青少年接种疫苗之前,它不会寻求批准其疫苗在幼儿中的使用。强生(音译)是第三种获准在美国使用的疫苗,他正在研究这种疫苗在青少年中的注射,但还没有开始在年幼的儿童身上研究。

Pfizer also raised its overall financial guidance for the year, forecasting sales of $81 billion to $82 billion, and adjusted earnings of $4.13 a share to $4.18 a share. It attributed the increase to both vaccine and nonvaccine momentum.

辉瑞还上调了今年的整体财务指引,预计销售额为810亿至820亿美元,调整后每股收益为4.13美元至4.18美元。它将这一增长归因于疫苗和非疫苗的势头。

Excluding the Covid-19 vaccine, sales of Pfizer's other drugs rose 7%. Oncology drug sales rose 12% to more than $3 billion, as sales jumped on breast-cancer treatment Ibrance and prostate-cancer drug Xtandi. Revenue for blood thinner rose 21% to more than $1.3 billion.

不包括新冠肺炎疫苗,辉瑞其他药物的销售额增长了7%.肿瘤药物销售额增长12%,超过30亿美元,乳腺癌治疗药物Ibrance和前列腺癌药物Xtandi的销售额跃升。血液稀释剂的收入增长了21%,超过13亿美元。

Stripping out one-time items, the company's adjusted third-quarter profit was $1.34 a share. Wall Street analysts had predicted $22.58 billion in revenue and adjusted earnings of $1.08 a share.

剔除一次性项目,该公司调整后的第三季度利润为每股1.34美元。华尔街分析师此前预测营收为225.8亿美元,调整后每股收益为1.08美元。

Write to Jared S. Hopkins at jared.hopkins@wsj.com and Matt Grossman at matt.grossman@wsj.com

写信给贾里德·S·霍普金斯(Jared S.Hopkins)(jared.Hopkins@wsj.com)和马特·格罗斯曼(Matt Grossman)(matt.grossman@wsj.com)

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发